Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: A retrospective study of 1875 cases in Taiwan

Journal of the Formosan Medical Association

Volumn 106, Issue 11, 2007, Pages 929-934

  Chiang, I Ni ^a   Chang, Shang Jen ^b   Pu, Yeong Shiau ^a   Huang, Kuo How ^a   Yu, Hong Jen ^a   Huang, Chao Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Complications; Morbidity; Risk factors; Transrectal ultrasound prostate needle biopsy; TRUS

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; LEVOFLOXACIN; PIPEMIDIC ACID; WARFARIN;

ADULT; AGE; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EPIDIDYMITIS; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PROSTATE BIOPSY; PROSTATITIS; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SINGLE DRUG DOSE; SYNCOPE; TAIWAN; TRANSRECTAL ULTRASONOGRAPHY; URINE RETENTION;

EID: 37349021005     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60063-7     Document Type: Article

References (15)

1. Fitzsimons NJ, Sun L, Moul JW. Medical technologies for the diagnosis of prostate cancer. Expert Rev Med Devices 2007;4:227-39.
2. Berger AP, Gozzi C, Steiner H, et aL Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004;171:1478-80.
3. Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001;166:856-60.
4. Chang CK, Yu HJ, Chan KW, Lai MK. Secular trend and age-period-cohort analysis of prostate cancer mortality in Taiwan. J Urol 1997;158:1845-8.
5. Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002;60:826-30.
6. Sech S, Montoya J, Girman CJ, et al. Interexaminer reliability of transrectal ultrasound for estimating prostate volume. J Urol 2001;166:125-9.
7. Taylor HM, Bingham JB. The use of prophylactic antibiotics in ultrasound-guided transrectal prostate biopsy. Clin Radiol 1997;52:787-90.
8. Larsson P, Norming U, Tomblom M, Gustafsson O. Antibiotic prophylaxis for prostate biopsy: benefits and costs. Prostate Cancer Prostatic Dis 1999;2:88-90.
9. Puig J, Darnell A, Bermudez P, et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol 2006-,16:939-43.
10. Sabbagh R, McCormack M, Peloquin F, et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol 2004; 11: 2216-9.
11. Tobias-Machado M, Correa TD, De Barros EL, Wroclawski ER. Antibiotic prophylaxis in prostate biopsy. A comparative randomized clinical assay between ciprofloxacin, norfloxacin and chloramphenicol. Int Braz J Urol 2003;29:313-9.
12. Yang L, Hu J, Wei H, et al. Clinical significance of antibiotic prophylaxis for transrectal prostate biopsy. Zhonghua Wai Ke Za Zhi 2001;39:940-2. [In Chinese]
13. Enlund AL, Varenhorst E. Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. Br J Urol 1997;79:777-80.
14. Griffith BC, Morey AF, Li-Khan MM, et al. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. J Urol 2002;168:1021-3.
15. Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol 2000;164:76-80.